Oruka Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Oruka Therapeutics, Inc. (ORKA), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are ORKA insiders buying or selling?
In the last 12 months, Oruka Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 39 sales ($335.6M) — net selling of $335.6M. Since February 2018, Trabud has recorded 78 Form 4 filings for ORKA: 24 buys ($5.9M) and 54 sells ($343.8M).
Source: SEC EDGAR Form 4
Key Statistics (February 2018 – Oct 2, 2026)
Total Form 4 filings
78
SEC EDGAR
Insider filers
25
Insider buys (24)
$5.9M
Insider sells (54)
$343.8M
Insider sentiment
Net sellingNet insider flow of $337.9M in net selling since February 2018, and $335.6M in net selling over the last 12 months.
Recent ORKA insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 2, 2026 | Lawrence Otto Klein | Chief Executive Officer | Sale | 25.0K | $83.62 | $2.1M | SEC ↗ |
| Sep 21, 2026 | Arjun Agarwal | Senior Vice President, Finance | Sale | 533 | $95.75 | $51.0K | SEC ↗ |
| Sep 21, 2026 | Paul T Quinlan | General Counsel | Sale | 10.0K | $93.64 | $936.4K | SEC ↗ |
| Sep 15, 2026 | Joana Goncalves | Chief Medical Officer | Sale | 7.9K | $92.38 | $734.1K | SEC ↗ |
| Sep 15, 2026 | Arjun Agarwal | Senior Vice President, Finance | Sale | 10.0K | $92.43 | $926.0K | SEC ↗ |
| Sep 15, 2026 | Lawrence Otto Klein | Chief Executive Officer | Sale | 2.5K | $95.71 | $234.7K | SEC ↗ |
| Sep 15, 2026 | Paul T Quinlan | General Counsel | Sale | 1.0K | $95.71 | $99.4K | SEC ↗ |
| Sep 15, 2026 | Laura Lee Sandler | Chief Operating Officer | Sale | 906 | $95.71 | $86.7K | SEC ↗ |
| Sep 1, 2026 | Laura Lee Sandler | Chief Operating Officer | Sale | 5.0K | $91.82 | $459.1K | SEC ↗ |
| Sep 1, 2026 | Lawrence Otto Klein | Chief Executive Officer | Sale | 75.0K | $91.83 | $6.9M | SEC ↗ |
| Aug 17, 2026 | Joana Goncalves | Chief Medical Officer | Sale | 7.0K | $111.84 | $782.9K | SEC ↗ |
| Aug 14, 2026 | Paul T Quinlan | General Counsel | Sale | 52.0K | $108.49 | $5.6M | SEC ↗ |
| Aug 14, 2026 | Arjun Agarwal | Senior Vice President, Finance | Sale | 10.0K | $106.66 | $1.1M | SEC ↗ |
| Jul 15, 2026 | Joana Goncalves | Chief Medical Officer | Sale | 7.0K | $86.28 | $603.9K | SEC ↗ |
| Jul 13, 2026 | Arjun Agarwal | Senior Vice President, Finance | Sale | 10.0K | $84.63 | $846.2K | SEC ↗ |
| Jul 2, 2026 | Fairmount Funds Management LLC | Director, 10% Owner | Sale | 3.6M | $84.43 | $300.0M | SEC ↗ |
| Jul 1, 2026 | Laura Lee Sandler | Chief Operating Officer | Sale | 5.0K | $94.42 | $472.1K | SEC ↗ |
| Jun 22, 2026 | Arjun Agarwal | Senior Vice President, Finance | Sale | 1.6K | $80.95 | $128.5K | SEC ↗ |
| Jun 15, 2026 | Arjun Agarwal | Senior Vice President, Finance | Sale | 9.9K | $69.72 | $687.0K | SEC ↗ |
| Jun 15, 2026 | Joana Goncalves | Chief Medical Officer | Sale | 7.9K | $69.28 | $550.6K | SEC ↗ |
| Jun 15, 2026 | Lawrence Otto Klein | Chief Executive Officer | Sale | 1.7K | $69.69 | $120.5K | SEC ↗ |
| Jun 15, 2026 | Laura Lee Sandler | Chief Operating Officer | Sale | 600 | $69.69 | $41.8K | SEC ↗ |
| Jun 15, 2026 | Paul T Quinlan | General Counsel | Sale | 733 | $69.69 | $51.1K | SEC ↗ |
| Jun 12, 2026 | Carl Dambkowski | Director | Sale | 35.0K | $70.13 | $2.5M | SEC ↗ |
| May 22, 2026 | Carl Dambkowski | Director | Sale | 105.0K | $58.97 | $6.2M | SEC ↗ |
Showing the 25 most recent of 78 Form 4 filings for Oruka Therapeutics, Inc..
Most active ORKA insiders
- Funicular Fund, LP13 filings
- Joana Goncalves10 filings
- Arjun Agarwal8 filings
- Laura Lee Sandler8 filings
- Robert E Conway6 filings
Ask anything about ORKA insider activity
Use Trabud's AI agent to query Oruka Therapeutics, Inc.'s Form 4 history in plain English — "Show me ORKA CEO purchases this year" or compare it against any other ticker.
Open the AI agentORKA insider trading FAQ
Are Oruka Therapeutics, Inc. insiders buying or selling?
In the last 12 months, Oruka Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 39 sales ($335.6M) — net selling of $335.6M. Since February 2018, Trabud has recorded 78 Form 4 filings for ORKA: 24 buys ($5.9M) and 54 sells ($343.8M). Over the full record that is net selling of $337.9M.
How many insiders trade ORKA stock?
25 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Oruka Therapeutics, Inc.. The most recent filing was accepted on Oct 2, 2026.
Where does Trabud get ORKA insider trading data?
All ORKA insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.